Furthermore, the transcription factor p-ERK was investigated via an activation profiling array, which showed that only the activity of the transcription factor Ets1 was significantly inhibited in colon cancer cells treated with NCTD. The gene discussed is MAPK1; the disease is malignant colon neoplasm.